Island Pharmaceuticals Limited (ILA.AX)

AUD 0.18

(2.94%)

Market Cap (In AUD)

31.63 Million

Revenue (In AUD)

1.25 Million

Net Income (In AUD)

-2.86 Million

Avg. Volume

106.9 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.05-0.28
PE
-
EPS
-
Beta Value
0.052
ISIN
AU0000138869
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D.
Employee Count
-
Website
https://www.islandpharmaceuticals.com
Ipo Date
2021-04-13
Details
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.